

REMARKS

After entry of this amendment, claims 1-2, and 9-10 are pending in this application. Claims 1, 2, 9 and 10 are allowed. Claims 12-13 and 20-21 have been canceled. Applicants reserve their right to prosecute subject matter of canceled claims in subsequent applications.

No new matter has been added by these amendments.

Claim Rejections under 35 USC §112, first paragraph

Claims 12, and dependent claims 13, 17, 20 and 21 remain rejected under 35 USC § 112, first paragraph, as the specification allegedly does not describe the claimed method for identifying an inhibitor of FtsZ-mt activity having antimicrobial activity.


Applicants respectfully disagree with this rejection. However, in order to obtain patent protection of the allowed claims, applicants have canceled claims 12, 13, 17, 20 and 21. Therefore, this rejection is moot.

In conclusions, the above remarks and amendments place the application in form for allowance. Please contact Mary Kakefuda at the telephone number below if you have any questions.

Syngenta Biotechnology, Inc.
3054 Cornwallis Road
Research Triangle Park, NC 27709-2257

Date: March 4, 2004

Respectfully submitted,



Mary Kakefuda
Attorney for Applicants
Registration No. 39,245
Telephone: 919-765-5071